Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis.

Proteasome inhibition has been shown to prevent development of fibrosis in several organs including the lung. However, effects of proteasome inhibitors on lung fibrosis are controversial and cytotoxic side effects of the overall inhibition of proteasomal protein degradation cannot be excluded. There...

Full description

Bibliographic Details
Main Authors: Nora Semren, Nunja C Habel-Ungewitter, Isis E Fernandez, Melanie Königshoff, Oliver Eickelberg, Tobias Stöger, Silke Meiners
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4560391?pdf=render